Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Conavi Medical ( (TSE:CNVI) ) has provided an update.
Conavi Medical has submitted its next-generation Novasight Hybrid intravascular imaging system to the U.S. FDA for 510(k) clearance, marking a significant milestone in its efforts to enter the U.S. market. The new system, which combines enhanced IVUS and OCT imaging capabilities, aims to improve procedural outcomes in coronary interventions. With the coronary intravascular imaging market projected to grow significantly, the company is poised to capitalize on the increasing adoption of advanced imaging technologies, supported by recent U.S. and European guidelines recommending the use of IVUS or OCT in complex coronary procedures.
The most recent analyst rating on (TSE:CNVI) stock is a Buy with a C$1.00 price target. To see the full list of analyst forecasts on Conavi Medical stock, see the TSE:CNVI Stock Forecast page.
More about Conavi Medical
Conavi Medical is a commercial-stage medical device company that specializes in designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures. Its flagship product, the Novasight Hybrid™ System, uniquely combines intravascular ultrasound (IVUS) and optical coherence tomography (OCT) into a single device, providing comprehensive imaging solutions for coronary arteries. The company has regulatory clearance for its first-generation system in the U.S., Canada, China, and Japan.
Average Trading Volume: 42,278
Technical Sentiment Signal: Sell
Current Market Cap: C$26.72M
Learn more about CNVI stock on TipRanks’ Stock Analysis page.